Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents

Status unconfirmed

Conditions studied: Hepatocellular Carcinoma

In brief

This study aims to determine whether or not gadoxetate disodium (Eovist) enhanced magnetic resonance imaging (MRI) has a higher sensitivity for detecting hepatocellular carcinoma (Liver Cancer) comparison to multi-detector computed tomography (CT).

Key facts

Study ID

NCT01341132

Run by

San Francisco Veterans Affairs Medical Center

People needed

75

Starts

2011-05-01

Last updated by the study team

2011-04-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Alpha-feto protein > 400 ng / mL or
• prior ultrasound with mass suspicious for hepatic malignancy or.
• clinical risk of hepatocellular carcinoma or
• prior multi-detector CT with mass suspicious for possible hepatocellular carcinoma

You may not qualify if…

• Glomerulo-filtration rate < 50 mL/ min/1.73 m2 based on a creatinine measurement within three months of the MR study
• Previous diagnosis of hepatic malignancy
• Any conditions that would discount the ability to have an MRI scan

Where it is running

• San Francisco VA Medical Center — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.